1Krauss, RM & Burke, DJ (1982) Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23, 97–104.
2Lamarche, B, Tchernof, A, Moorjani, S, Cantin, B, Dagenais, GR, Lupien, PJ & Despres, JP (1997) Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95, 69–75.
3St Pierre, AC, Ruel, IL, Cantin, B, Dagenais, GR, Bernard, PM, Despres, JP & Lamarche, B (2001) Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 104, 2295–2299.
4Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389.
5Anon, MRC/BHF (2002) Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22.
6Grundy, SM (1988) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319, 24–33.
7Zhao, SP, Hollaar, L, ’t Hooft, FM, Smelt, AH, Gevers, JA & van der Leuven, LA (1991) Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia. Clin Chim Acta 203, 109–117.
8Yuan, JN, Tsai, MY, Hegland, J & Hunninghake, DB (1991) Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 87, 147–157.
9Forster, LF, Stewart, G, Bedford, D, Stewart, JP, Rogers, E, Shepherd, J, Packard, CJ & Caslake, MJ (2002) Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164, 129–145.
10Guerin, M, Egger, P, Soudant, C, Le Goff, W, van Tol, A, Dupuis, R & Chapman, MJ (2002) Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163, 287–296.
11Marz, W, Scharnagl, H, Abletshauser, C, Hoffmann, MM, Berg, A, Keul, J, Wieland, H & Baumstark, MW (2001) Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 103, 1942–1948.
12Superko, HR, Krauss, RM & DiRicco, C (1997) Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol 80, 78–81.
13Tilly-Kiesi, M (1991) The effect of lovastatin treatment on low-density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia. Metabolism 40, 623–628.
14Yu-Poth, S, Zhao, G, Etherton, T, Naglak, M, Jonnalagadda, S & Kris-Etherton, PM (1999) Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr 69, 632–646.
15 (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486–2497.
16Krauss, RM, Eckel, RH, Howard, B, et al. (2000) AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102, 2284–2299.
17Jenkins, DJ, Kendall, CW, Marchie, A, et al. (2005) Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr 81, 380–387.
18Almario, RU, Vonghavaravat, V, Wong, R & Kasim-Karakas, SE (2001) Effects of walnut consumption on plasma fatty acids and lipoproteins in combined hyperlipidemia. Am J Clin Nutr 74, 72–79.
19Charest, A, Desroches, S, Vanstone, CA, Jones, PJ & Lamarche, B (2004) Unesterified plant sterols and stanols do not affect LDL electrophoretic characteristics in hypercholesterolemic subjects. J Nutr 134, 592–595.
20Charest, A, Vanstone, C, St Onge, MP, Parson, W, Jones, PJ & Lamarche, B (2005) Phytosterols in nonfat and low-fat beverages have no impact on the LDL size phenotype. Eur J Clin Nutr 59, 801–804.
21Davy, BM, Davy, KP, Ho, RC, Beske, SD, Davrath, LR & Melby, CL (2002) High-fiber oat cereal compared with wheat cereal consumption favorably alters LDL-cholesterol subclass and particle numbers in middle-aged and older men. Am J Clin Nutr 76, 351–358.
22Desroches, S, Mauger, JF, Ausman, LM, Lichtenstein, AH & Lamarche, B (2004) Soy protein favorably affects LDL size independently of isoflavones in hypercholesterolemic men and women. J Nutr 134, 574–579.
23Matvienko, OA, Lewis, DS, Swanson, M, Arndt, B, Rainwater, DL, Stewart, J & Alekel, DL (2002) A single daily dose of soybean phytosterols in ground beef decreases serum total cholesterol and LDL cholesterol in young, mildly hypercholesterolemic men. Am J Clin Nutr 76, 57–64.
24Merz-Demlow, BE, Duncan, AM, Wangen, KE, Xu, X, Carr, TP, Phipps, WR & Kurzer, MS (2000) Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. Am J Clin Nutr 71, 1462–1469.
25Wangen, KE, Duncan, AM, Xu, X & Kurzer, MS (2001) Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am J Clin Nutr 73, 225–231.
26Varady, KA, St Pierre, AC, Lamarche, B & Jones, P (2005) Effect of plant sterols and endurance training on LDL particle size and distribution in previously sedentary hypercholesterolemic adults. Eur J Clin Nutr 59, 518–525.
27Behall, KM, Scholfield, DJ & Hallfrisch, J (2004) Diets containing barley significantly reduce lipids in mildly hypercholesterolemic men and women. Am J Clin Nutr 80, 1185–1193.
28Lamarche, B, Desroches, S, Jenkins, DJ, et al. (2004) Combined effects of a dietary portfolio of plant sterols, vegetable protein, viscous fibre and almonds on LDL particle size. Br J Nutr 92, 657–663.
29Desroches, S, Archer, WR, Paradis, ME, Deriaz, O, Couture, P, Bergeron, J, Bergeron, N & Lamarche, B (2006) Baseline plasma C-reactive protein concentrations influence lipid and lipoprotein responses to low-fat and high monounsaturated fatty acid diets in healthy men. J Nutr 136, 1005–1011.
30Erlinger, TP, Miller, ERIII, Charleston, J & Appel, LJ (2003) Inflammation modifies the effects of a reduced-fat low-cholesterol diet on lipids: results from the DASH-sodium trial. Circulation 108, 150–154.
31Hilpert, KF, Kris-Etherton, PM & West, SG (2005) Lipid response to a low-fat diet with or without soy is modified by C-reactive protein status in moderately hypercholesterolemic adults. J Nutr 135, 1075–1079.
32Jenkins, DJ, Kendall, CW, Marchie, A, et al. (2005) Direct comparison of dietary portfolio vs statin on C-reactive protein. Eur J Clin Nutr 59, 851–860.
33Jenkins, DJ, Kendall, CW, Faulkner, D, et al. (2002) A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism 51, 1596–1604.
34Pearson, TA, Mensah, GA, Alexander, RW, et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499–511.
35Yudkin, JS, Kumari, M, Humphries, SE & Mohamed-Ali, V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148, 209–214.